TIAA CREF Investment Management LLC cut its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 6.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,686 shares of the biopharmaceutical company’s stock after selling 8,815 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.24% of Theravance Biopharma worth $4,665,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at about $464,000. State Street Corp increased its position in shares of Theravance Biopharma by 18.3% in the fourth quarter. State Street Corp now owns 851,024 shares of the biopharmaceutical company’s stock valued at $27,136,000 after buying an additional 131,646 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Theravance Biopharma by 153.3% in the fourth quarter. Two Sigma Investments LP now owns 26,931 shares of the biopharmaceutical company’s stock valued at $859,000 after buying an additional 16,299 shares in the last quarter. Norges Bank purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at about $27,631,000. Finally, Teachers Advisors LLC increased its position in shares of Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock valued at $2,218,000 after buying an additional 11,201 shares in the last quarter. Hedge funds and other institutional investors own 84.30% of the company’s stock.
Theravance Biopharma, Inc. (TBPH) opened at 36.37 on Friday. The company’s 50-day moving average is $39.20 and its 200-day moving average is $35.62. Theravance Biopharma, Inc. has a 12 month low of $22.13 and a 12 month high of $43.44. The company’s market cap is $1.94 billion.
Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.14) by $0.13. The company had revenue of $3.09 million during the quarter, compared to analyst estimates of $5.07 million. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%. On average, equities research analysts expect that Theravance Biopharma, Inc. will post ($4.61) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/22/tiaa-cref-investment-management-llc-has-4-67-million-stake-in-theravance-biopharma-inc-tbph.html.
TBPH has been the topic of several analyst reports. Needham & Company LLC upped their target price on shares of Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. Leerink Swann set a $47.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, May 10th. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 16th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Theravance Biopharma currently has a consensus rating of “Hold” and a consensus price target of $41.13.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
